- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05838625
Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia (CONVOKE)
March 13, 2024 updated by: Click Therapeutics, Inc.
A Randomized, Multicenter, 16-week Study to Evaluate the Efficacy and Safety of Two Prescription Digital Therapeutics as an Adjunct to Standard-of-Care Antipsychotic Therapy in Adult and Late Adolescent Participants With Experiential Negative Symptoms of Schizophrenia
This study evaluates the efficacy of two prescription digital therapeutics (PDT) in addition to standard of care (SOC) therapy for the treatment of experiential negative symptoms of schizophrenia in late adolescents and adults.
Study Overview
Detailed Description
The purpose of the proposed study is to evaluate the efficacy and safety of two prescription digital therapeutics as an adjunct treatment to SOC in participants 18 years of age or older diagnosed with experiential negative symptoms of schizophrenia.
Study Type
Interventional
Enrollment (Estimated)
432
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Research Coordinator
- Phone Number: 877-352-5425
- Email: researchcoordinator@clicktherapeutics.com
Study Locations
-
-
New York
-
New York, New York, United States, 10013
- Recruiting
- Click Therapeutics
-
Contact:
- Research Coordinator
- Phone Number: 877-352-5425
- Email: researchcoordinator@clicktherapeutics.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
A participant will be eligible for entry into the study if all of the following criteria are met:
- Has a primary diagnosis of schizophrenia.
- Is on a stable dose of antipsychotic medication(s).
- Has obtained an average score of ≥2 (moderate to severe) in at least two of the three CAINS-MAP domains (Social, Work, or Recreational).
Exclusion Criteria:
A participant will not be eligible for study entry if any of the following criteria are met:
- Is currently treated with more than two antipsychotic medications (including more than two dosage forms).
- Meets DSM-5, for diagnoses not under investigation.
- Has participated in a CT-155 clinical study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Digital Therapeutic A
Evaluate the efficacy and safety of digital therapeutic A as an adjunct treatment to SOC in participants with experiential negative symptoms of schizophrenia.
|
A prescription digital therapeutic in the form of a smartphone app.
|
Experimental: Digital Therapeutic B
Evaluate the efficacy and safety of digital therapeutic B as an adjunct treatment to SOC in participants with experiential negative symptoms of schizophrenia.
|
A prescription digital therapeutic in the form of a smartphone app.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Experiential negative symptoms
Time Frame: Baseline to Week 16
|
Change from baseline to Week 16 in experiential negative symptoms, as assessed by Clinical Assessment Interview for Negative Symptoms, Motivation and Pleasure Scale (CAINS-MAP)
|
Baseline to Week 16
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Motivation and pleasure symptoms
Time Frame: Baseline to Week 8
|
Change from baseline in motivation and pleasure symptoms at Week 8, as assessed by CAINS-MAP
|
Baseline to Week 8
|
Expressive negative symptoms
Time Frame: Baseline to Weeks 8 and 16
|
Change from baseline in expressive negative symptoms at Weeks 8 and 16, as assessed by the Clinical Assessment Interview for Negative Symptoms, Expressivity Scale (CAINS-EXP)
|
Baseline to Weeks 8 and 16
|
Positive symptoms
Time Frame: Baseline to Weeks 8 and 16
|
Change from baseline in positive symptoms at Weeks 8 and 16, as assessed by the Positive and Negative Syndrome Scale (PANSS)
|
Baseline to Weeks 8 and 16
|
Social functioning
Time Frame: Baseline to Weeks 8 and 16
|
Change from baseline in social functioning at Weeks 8 and 16, as assessed by the Personal and Social Performance Scale (PSP)
|
Baseline to Weeks 8 and 16
|
Self-reported defeatist beliefs
Time Frame: Baseline to Weeks 8 and 16
|
Change from baseline in self-reported defeatist beliefs at Weeks 8 and 16, as assessed by the Defeatist Beliefs Subscale of the Dysfunctional Attitudes Scale (DAS)
|
Baseline to Weeks 8 and 16
|
Patient global impression of improvement
Time Frame: Weeks 8 and 16
|
Patient Global Impression of Improvement Scale (PGI-I) at Weeks 8 and 16
|
Weeks 8 and 16
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: Shaheen Lakhan, MD, PhD, FAAN, Click Therapeutics
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 31, 2023
Primary Completion (Estimated)
June 18, 2025
Study Completion (Estimated)
July 18, 2025
Study Registration Dates
First Submitted
April 20, 2023
First Submitted That Met QC Criteria
April 20, 2023
First Posted (Actual)
May 1, 2023
Study Record Updates
Last Update Posted (Actual)
March 15, 2024
Last Update Submitted That Met QC Criteria
March 13, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CT-155-R-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
Peking UniversityNot yet recruitingTreatment-resistant Schizophrenia
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
-
NYU Langone HealthNot yet recruitingTreatment-resistant SchizophreniaUnited States
Clinical Trials on Digital Therapeutic
-
Sun Yat-sen UniversityRecruitingApplication of Digital Therapeutic in Lung Cancer Whole Process ManagementChina
-
Stanford UniversityEnrolling by invitationAutism Spectrum Disorder | AutismUnited States
-
University of British ColumbiaUnknown
-
COG AnalyticsFriends Research Institute, Inc.Completed
-
Karuna Labs Inc.CompletedLow Back Pain | Chronic Pain | Shoulder PainUnited States
-
Shanghai University of Traditional Chinese MedicineRecruitingCervical SpondylosisChina
-
Click Therapeutics, Inc.Active, not recruitingMigraine | Headache | Headache, Migraine | Episodic MigraineUnited States
-
University of WashingtonNational Center for Complementary and Integrative Health (NCCIH)Active, not recruiting
-
Click Therapeutics, Inc.Active, not recruitingMigraine | Headache | Headache, Migraine | Episodic MigraineUnited States
-
Habitual Health LtdLindus HealthEnrolling by invitation